- ►pipex.com [PDF] RR Holman, KI Thorne, AJ Farmer, MJ Davies … - New England Journal …, 2007 - content.nejm.org From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism (RRH, KIT,
AJF, JFK, SP, JCL) and the Department of Primary Health Care (AJF), University of Oxford, Oxford;
and the Department of Cardiovas- ... Cited by 137 - Related articles - BL Direct - All 12 versions
RG Bretzel, U Nuber, W Landgraf, DR Owens, C … - The Lancet, 2008 - Elsevier In the 44-week, parallel, open study that was undertaken in 69 study sites across Europe and
Australia, 418 patients with type 2 diabetes mellitus that was inadequately controlled by oral
hypoglycaemic agents were randomly ... Cited by 50 - Related articles - All 24 versions
T Heise, TR Pieber - Diabetes Obes Metab, 2007 - journals.pcommed.com While the advantages of the two basal insulin analogues, glargine and detemir, over neutral
protamine Hagedorn are well established, the relative merit of the two compared with each other has
been a matter of some controversy. ... Cited by 46 - Related articles - View as HTML - All 4 versions
SA Amiel, T Dixon, R Mann, K Jameson - Diabetic Medicine, 2008 - pubmedcentral.nih.gov The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication—in particular, those
which raise insulin levels independently of blood glucose, such as sulphonylureas (SUs) and
exogenous insulin. The risk of ... Cited by 31 - Related articles - BL Direct - All 7 versions
D Raccah, RG Bretzel, D Owens, M … - Diabetes/Metabolism … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 23 - Related articles - BL Direct - All 3 versions
H Yki-Järvinen, L Juurinen, M Alvarsson, T Bystedt, … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A randomized (1:1), multicenter, two-arm, parallel design study with a
recruiting period of up to 14 weeks and a 24-week treatment period. Either in groups of 4–8 or
individually, using the same ... Cited by 20 - Related articles - BL Direct - All 5 versions
L Meneghini, C Koenen, W Weng, JL … - Diabetes, Obesity & …, 2007 - pt.wkhealth.com The Predictable Results and Experience in Diabetes through Intensification and Control to Target: An
International Variability Evaluation 303 (PREDICTIVE™ 303) Study (n = 5604) evaluated the
effectiveness of insulin detemir, a ... Cited by 18 - Related articles - All 4 versions
Y Gao, XH Guo, JA Vaz… - Diabetes, obesity & metabolism, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 17 - Related articles - All 4 versions
S Chatterjee, JR Tringham, MJ … - Expert Opin. …, 2006 - informahealthcare.com Insulin treatment in Type 1 and Type 2 diabetes has come a long way since its discovery by Banting
and Best in 1922. Early insulin therapy was life-saving, but was associated with practical problems
and had side effects such as ... Cited by 14 - Related articles - BL Direct - All 5 versions
H Thisted, SP Johnsen, J Rungby - Basic & Clinical …, 2006 - interscience.wiley.com Abstract: For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk
of long-term complications. However, this must be achieved with minimal risk of hypoglycaemia.
Glargine is a new long-acting ... Cited by 14 - Related articles - BL Direct - All 6 versions
